2025 Bladder Cancer Think Tank Meeting

The 2025 Bladder Cancer Think Tank (#BCANTT25) convened in Washington, DC, from July 30 to August 1. Once again, BCAN united a diverse community of clinicians, researchers, patient and caregiver advocates, and industry partners—all committed to the shared goal of creating more and better tomorrows for bladder cancer patients and their loved ones.

BCANTT25 fostered dynamic, collaborative discussions across plenary and breakout sessions. The event also welcomed a new class of eight distinguished John Quale Travel Fellows—representing the next generation of leaders in bladder cancer research and patient care.

For more information about the 2025 Think Tank meeting, we invite you to read the agenda.

Videos from Think Tank

Wednesday, August 30, 2025

Welcome and Opening Remarks

Welcome and opening remarks with BCAN Co-Founder Diane Zipursky Quale and CEO Meri-Margaret Deoudes

New Faces of Bladder Cancer

Meet the 2025 John Quale Travel Fellows

With introduction by Scientific Review Group Chair, Max Kates, MD, Johns Hopkins Medicine

Thursday, July 31, 2025

BCAN 2024 Patient-Centered Clinical Research Young Investigator Awardee and Young Investigator Awardees

With introductions by Scientific Review Group Chair, Lindsey Herrel, MD, MS, University of Michigan and Scientific Review Group Chair, Neelam Mukherjee, PhD, University of Texas Health Center San Antonio

  • Patient-Centered Clinical Research Young Investigator Awardee: Divya Ajay, MD, MPH, Memorial Sloan Kettering Cancer Center: Enhancing patient-centered care with a decision support tool for choosing urinary diversions for bladder cancer patients undergoing radical cystectomy.
  • Young Investigator Awardee: Jonathan Anker, MD, PhD, Icahn School of Medicine at Mount Sinai: Characterizing and modulating TREM1 on SPP1 macrophages to overcome resistance to immunotherapy in urothelial cancer.
  • Young Investigator Awardee: Lucas Blanchard, PhD, The Rockefeller University: Targeting regulatory T cells (Tregs) to improve antitumor immunity in BCG-unresponsive non-muscle invasive bladder cancer

Lessons Learned from Clinical Trials

Co-Chairs: Seth Lerner, MD, Baylor College of Medicine; and Andrea Apolo, MD,
National Institutes of Health

Friday, August 1st

BCAN 2023 Bladder Cancer Research Innovation Awardees

Christopher Garris, PhD, Massachusetts General Hospital: Overcoming immune
suppressive myeloid cell barriers in bladder cancer

John Taylor, MD, MS, University of Kansas Medical Center: Exploring therapeutic
vulnerabilities for drug development in bladder cancer using Down Syndrome
as a novel model

Balancing Innovation and Affordability: Collaborative Pathways in Bladder Cancer Care

Co-Chairs: Parminder Singh, MD, Mayo Clinic; Matthew Mossanen, MD, MPH,
Brigham and Women’s Hospital, Harvard Medical School; and Ruchika Talwar, MD,
MMHC, Vanderbilt University Medical Center

Think Tank Photos